Jade Biosciences to Discuss JADE101 Phase 1 Results June 1

Key Highlights

• Jade Biosciences will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET.
• The call will discuss results from the ongoing Phase 1 healthy volunteer study of JADE101.
• Data are expected to define the dosing strategy and characterize JADE101’s clinical profile.
• JADE101 is a potentially differentiated anti–APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN).
• IgAN is a chronic autoimmune kidney disease affecting approximately 169,000 people in the U.S.
• JADE101 is a fully human monoclonal antibody engineered for half-life extension, showing potent IgA suppression in preclinical studies.
• The company's pipeline also includes JADE201 and JADE301.
• Investors and the public can register for the webcast on the company’s website.